Inmagene Biopharmaceuticals and Hutchmed (China) have dosed the first participant in a global Phase I trial of OX40 antagonistic monoclonal antibody, IMG-007. The multi-stage trial is recruiting healthy participants and adult patients with moderate-to-severe atopic dermatitis.

The double-blind, placebo-controlled, randomised, dose-escalation Phase I study has been designed to assess IMG-007’s tolerability, safety, and efficacy. It is a dose-escalation and parallel design, multiple-dose study.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

IMG-007 targets the OX40 receptor, a costimulatory receptor member of the tumour necrosis factor receptor (TNFR) superfamily expressed predominantly on activated T cells.

Originally, it was originally discovered by HUTCHMED and later Inmagene assumed the development responsibility at the candidate stage.

Inmagene holds an exclusive option to in-license global rights of the antibody.

See Also:

Inmagene chief development officer Dr Jean-Louis Saillot said: “IMG-007 blocks the OX40 activity and has demonstrated high potency in preclinical studies, indicating a best-in-class potential.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We welcome the start of the IMG-007 clinical programme with the hope of developing an innovative, safe and effective treatment option for patients with atopic dermatitis and other immunological diseases.”

Inmagene chairman and CEO Dr Jonathan Wang said: “Dosing the first participant is an important milestone for the IMG-007 programme.

“We hope the data will help us demonstrate that IMG-007 is one of the strongest OX40 antagonist drug candidates worldwide.”

In May this year, Inmagene received the US Food and Drug Administration (FDA) clearance for its drug candidate, IMG-004, to be investigated in a Phase I clinical trial.